Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.37 |
| ▸ | PYGB | P11216 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL33302 | 1.00 | MAPK1 (0.64) | MAPK1NOD2ALDH1A1THRBLGALS8 | |
| SCHEMBL30987364 | 1.00 | MAPK1 (0.64) | MAPK1NOD2ALDH1A1THRBLGALS8 | |
| SCHEMBL16241536 | 1.00 | MAPK1 (0.64) | MAPK1NOD2ALDH1A1THRBLGALS8 | |
| SCHEMBL42791 | 1.00 | MAPK1 (0.64) | MAPK1NOD2ALDH1A1THRBLGALS8 | |
| SCHEMBL2728425 | 1.00 | MAPK1 (0.64) | MAPK1NOD2ALDH1A1THRBLGALS8 | |
| SCHEMBL16241534 | 1.00 | MAPK1 (0.64) | MAPK1NOD2ALDH1A1THRBLGALS8 | |
| SCHEMBL42792 | 1.00 | MAPK1 (0.64) | MAPK1NOD2ALDH1A1THRBLGALS8 | |
| SCHEMBL17184967 | 1.00 | MAPK1 (0.64) | MAPK1NOD2ALDH1A1THRBLGALS8 | |
| SCHEMBL22163862 | 1.00 | MAPK1 (0.64) | MAPK1NOD2ALDH1A1THRBLGALS8 | |
| Water SCHEMBL2557169 | 0.99 | MAPK1 (0.63) | MAPK1NOD2ALDH1A1THRBLGALS8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 311 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106279308-A | The method utilizing the dreg separation 3-O-.alpha.-carboxyethyl-D-glucosamine. producing glutamic acid | 山东师范大学 | 2017-01-04 | — | — | CN | claimed |
| CN-106188171-A | A kind of method utilizing the dreg producing glutamic acid to prepare 3-O-.alpha.-carboxyethyl-D-glucosamine. | 山东师范大学 | 2016-12-07 | — | — | CN | claimed |
| CN-104053702-B | The method of preparation sugar silicone copolymers | 道康宁公司 | 2016-06-22 | — | — | CN | claimed |
| CN-101282708-B | External preparation for skin containing a phosphorlated saccharide | EZAKI GLICO CO | 2013-03-20 | — | — | CN | claimed |
| CN-102421452-A | Multivalent adjuvant display | HYBRID BIOSYSTEMS LTD | 2012-04-18 | — | — | CN | claimed |
| CN-101766550-A | Combination of monosaccharides and ascorbic acid and its use in cosmetic | OREAL | 2010-07-07 | — | — | CN | claimed |
| CN-1917886-A | Core 2 glcnac-t inhibitors | BTG INT LTD (GB) | 2007-02-21 | — | — | CN | claimed |
| CN-1665494-A | Polymeric affinity matrices, methods of production and uses thereof | GAMBRO LUNDIA AB (SE) | 2005-09-07 | — | — | CN | claimed |
| CN-1203791-A | Vital engineering, factor and factor inducing, expressing regulation area and construction | LI JI (CN) | 1999-01-06 | — | — | CN | claimed |
| US-20260139285-A1 | SACCHARIDE IMPORTERS FOR LACTO-N-TRIOSE | INBIOSE N V (BE) | 2026-05-21 | — | — | US | disclosed |
| US-20250361477-A1 | PRODUCTION OF AN OLIGOSACCHARIDE MIXTURE BY A CELL | INBIOSE NV (BE) | 2025-11-27 | — | — | US | disclosed |
| US-20250188504-A1 | PRODUCTION OF A MIXTURE OF MAMMALIAN MILK OLIGOSACCHARIDES BY A CELL | INBIOSE N.V. (BE) | 2025-06-12 | — | — | US | disclosed |
| US-20250188503-A1 | SIALYLTRANSFERASES FOR THE PRODUCTION OF SIALYLATED OLIGOSACCHARIDES | INBIOSE N.V. (BE) | 2025-06-12 | — | — | US | disclosed |
| US-20250043253-A1 | SIALYLTRANSFERASES FOR THE PRODUCTION OF SIALYLATED OLIGOSACCHARIDES | INBIOSE N.V. (BE) | 2025-02-06 | — | — | US | disclosed |
| CN-1052167-C | multilayer material | NOVARTIS AG (CH) | 2000-05-10 | — | — | CN | disclosed |
| CN-1238216-A | Oral immunity enhancing agent | AJINOMOTO KK (JP) | 1999-12-15 | — | — | CN | disclosed |
| CN-1237911-A | Optical diagnostic agents for diagnosis of neurodenerative diseases by means of near infra-red radiation (NIR-Radiation) | DIAGNOSTIKFORSCHUNG INST (DE) | 1999-12-08 | — | — | CN | disclosed |
| CN-1203791-A | Vital engineering, factor and factor inducing, expressing regulation area and construction | LI JI (CN) | 1999-01-06 | — | — | CN | disclosed |
| CN-1127474-A | Dried hydrogel from hydrophylic-hygroscopic polymer | CARRINGTON LAB INC (US) | 1996-07-24 | — | — | CN | disclosed |
| CN-1094288-A | Utilize nocardia rubra to make the method for cell wall skeleton powder | FUJIAN PROV MICROORGANIC INST (CN) | 1994-11-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260139285-A1 | SACCHARIDE IMPORTERS FOR LACTO-N-TRIOSE | GALNT3, NANS, ENGASE | MAPK1 2418/4885NOD2 3422/4885ALDH1A1 3012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.